Ullernchausséen 64
Oslo 0379
Norway
47 41 38 00 80
https://www.ultimovacs.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 24
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Carlos de Sousa | Chief Executive Officer | 472,16k | N/A | 1958 |
Mr. Hans Vassgard Eid | Chief Financial Officer | 270,32k | N/A | N/A |
Ms. Ingunn Hagen Westgaard Ph.D. | Head of Research | 152,99k | N/A | N/A |
Mr. Audun Tornes | Chief Technology Officer | 177,59k | N/A | N/A |
Ms. Anne H. Worsoe | Head of Investor Relations & ESG | 157,1k | N/A | N/A |
Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer | 260,55k | N/A | N/A |
Mr. Oivind Foss Ph.D. | Head of Clinical Operations | 154,27k | N/A | N/A |
Ms. Gudrun Troite Ph.D. | Head of Project Coordination | 152,3k | N/A | N/A |
Mr. Antonius Berkien | Chief Business Officer | 281,98k | N/A | 1968 |
Orla Mc Callion | Head of Regulatory Affairs & QA | 145,96k | N/A | N/A |
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.